Pricing Log in Create free account
Saturday 7 November 2026 Export CHRS’s income statement to Excel — free account

Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

Coherus Oncology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $42.2 million, up 59.8% from fiscal 2024.

Revenue
+39.5%
EPS
−105.1%
Free cash flow
−33.2%
Total debt
+1.03%

Quarter to June 2026, against a year earlier

0.77 0.02 +2.67%
Market cap
$115.7M
P/E
0.0×
Fwd P/E
−0.9×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy — — — — — — — — — — — —
Sell — — — — — — — — — — — —
Insider Ownership 25.45%

Capital & Financial Ratios $m

Size
Market Cap 115.71
Revenue ttm 50.94
Net income ttm (132.13)
Free cash flow ttm (186.03)
Net debt Q (68.06)
Valuation
P/E 0.00
Forward P/E (0.88) (negative: loss-making)
Price / sales 2.34
Forward P/S Powerpack
Price / FCF 0.00
Price / book 1.96
Financial health
Current ratio Q 1.77 (at or above 1.5: strong)
Debt / equity Q 0.61
Interest coverage Q (13.92)
Growth
Revenue growth Q +39.53% (above 0%: growing)
Operating income growth Q +28.92% (above 0%: growing)
EPS, this year +43.78% (at or above 15%: strong)
EPS, next year A +8.74%
Revenue, next year A +44.20% (at or above 10%: strong)
EPS, past 5 yrs −2.46% (below 0%: weak)
EPS, next 5 yrs A +32.84% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 4.4×, against a ten-year median of 4.4×; over the ten years it ranged from 1.8× in 2024 to 513× in 2018.
P/S against its own 10 years 19.24%
10-year low 10-year high
P/B against its own 10 years 6.70%
10-year low 10-year high
EV/Sales against its own 10 years 49.16%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 118 126 172 105
Receivables 261 122 18 14
Inventory 63 4 3 6
Other 11 10 6 5
476 342 207 134
2023 2024 2025 Q'26
Payables 35 28 10 13
ST’ Debt — — — —
Other — — — —
332 283 140 76

Compound Annual Growth %

10y 5y 3y
Sales 3.09% (38.41%) (41.54%)
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 4.91% 0.00%
Book Value 0.00% (26.32%) 0.00%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate 0.08 Actual −0.19

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −0.32 −0.33 Miss by 0.01
Q4 FY25 −0.31 −0.34 Miss by 0.03
Q1 FY26 −0.18 −0.25 Miss by 0.07
Q2 FY26 0.08 −0.19 Miss by 0.27
Q3 FY26 −0.22 — Reports 9 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.28) (0.13) — — —
’25 (0.49) 2.57 (0.31) (0.31) 1.43
’24 0.83 (0.11) (0.09) (0.44) 0.25
’23 (0.96) (0.49) (0.41) (0.71) (2.53)
’22 (1.24) (0.65) (1.11) (0.76) (3.76)
’21 (2.37) (0.40) (0.49) (0.60) (3.81)
’20 0.48 0.70 0.33 0.12 1.62
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 12 14 — — —
’25 8 10 12 13 42
’24 2 10 6 8 26
’23 32 59 75 92 257
’22 60 60 45 45 211
’21 83 88 83 73 327
’20 116 136 114 110 476
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (58) (62) — — —
’25 (26) (47) (46) (20) (139)
’24 (47) 60 (62) 29 (20)
’23 (69) (39) (54) (13) (175)
’22 (54) (50) (37) (100) (241)
’21 1 0 14 (52) (37)
’20 13 60 47 33 154
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (58) (62) — — —
’25 (26) (47) (46) (20) (139)
’24 (47) 60 (62) 29 (20)
’23 (69) (39) (55) (13) (175)
’22 (55) (51) (38) (100) (243)
’21 1 (1) 13 (53) (39)
’20 12 58 45 32 147
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1.3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 190 2 — 356 476 327 211 257 26 42 51 (15.4%) 61 100 161 +56.4%
Gross margin, % 100.00 100.00 0.00 95.20 92.08 82.36 66.79 38.19 66.93 67.24 68.94 (32.8) pt
EBT (128) (238) (209) 93 136 (287) (292) (238) (215) (183) (161) +4.1%
EBT margin, % (67.22) (15,314.01) 0.00 26.06 28.52 (87.92) (138.24) (92.62) (816.23) (434.23) (316.37) (367.0) pt
Net income (128) (238) (209) 90 132 (287) (292) (238) 29 168 (132) n/m
Per share, $
Per share, $ Revenue 4.54 0.03 0.00 5.11 6.66 4.33 2.72 2.73 0.23 0.36 0.33 (24.5%)
Earnings (3.04) (4.48) (3.22) 1.29 1.85 (3.81) (3.76) (2.53) 0.25 1.43 (1.03) n/m
Cash flow (6.03) (3.77) (2.45) 0.41 2.16 (0.50) (3.11) (1.86) (0.18) (1.18) (1.20) (16.6%)
Capex (0.16) (0.09) (0.01) (0.03) (0.10) (0.02) (0.03) 0.00 0.00 0.00 0.00 n/m
Free cash flow (6.18) (3.86) (2.46) 0.38 2.06 (0.51) (3.13) (1.86) (0.18) (1.18) (1.20) (16.8%)
Book value 0.46 0.57 (0.59) 1.51 3.93 1.30 (1.77) (2.05) (1.15) 0.52 0.39 +1.3%
Shares, m 42 53 65 70 71 75 78 94 115 117 131 +12.1%
Valuation, ×
Valuation, × P/E 0.00 0.00 — 14.07 9.39 0.00 0.00 0.00 5.11 0.97 0.00 3.3
P/S 6.17 211.43 — 3.52 2.61 3.69 3.13 1.37 5.99 3.94 2.34 26.9
P/B 60.64 16.62 — 11.93 4.42 12.32 0.00 0.00 0.00 2.73 1.96 12.1
EV/Sales 6.04 200.86 — 3.53 2.33 4.04 4.47 2.77 17.89 4.89 4.44 27.4
EV/FCF (4.43) (2.35) — 47.41 7.54 (34.10) (3.88) (4.05) (22.08) (1.48) (1.21) (1.9)
Cash, $m
Cash, $m Operating cash flow (253) (200) (159) 28 154 (37) (241) (175) (20) (139) (186) (6.5%)
Capex (7) (5) (1) (2) (7) (1) (2) 0 — — (1) (36.0%)
Free cash flow (259) (205) (160) 27 147 (39) (243) (175) (20) (139) (186) (6.7%)
Balance, $m
Balance, $m Working capital 105 117 51 228 622 437 243 144 59 66 58 (5.0%)
Net debt (25) (25) 31 1 (137) (9) 279 356 139 (135) (68) +20.7%
Shareholders’ equity 19 31 (39) 105 281 98 (137) (193) (132) 61 61 +13.6%
Returns, %
Returns, % ROA (65.16) (139.65) (159.75) 35.34 21.15 (37.75) (50.29) (42.85) 5.29 47.54 (41.90) +112.7 pt
ROIC 0.00 (2,805.20) 0.00 63.58 67.92 (185.69) (113.10) (78.30) (1,795.44) 0.00 0.00 0.0 pt
ROE (2,049.69) (954.80) 5,197.10 269.68 68.49 (151.62) 1,470.09 143.81 (17.52) (473.47) (146.27) +1,576.2 pt
People
People Employees 152 122 232 291 317 332 359 306 306 147 — (0.4%)
Revenue/emp, $m 1.25 0.01 0.00 1.22 1.50 0.98 0.59 0.84 0.09 0.29 — (15.1%)
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026 · fundamentals updated 26 Oct 2026

Coherus Oncology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
CHRS Coherus Oncology, Inc. $115.7M — (loss-making) — (loss-making) +39.53% (above 0%: growing) n/m −33.15% (below 0%: shrinking) 70.35% (225.98%)
PYPD PolyPid Ltd. $115.2M — (loss-making) — — n/m −64.96% (below 0%: shrinking) 0.00% 0.00% Compare
FHTX Foghorn Therapeutics Inc. $113.1M — (loss-making) — (loss-making) +112.68% (above 0%: growing) n/m +14.88% (above 0%: growing) 100.00% (54.78%) Compare
ENGN enGene Therapeutics Inc $112.6M — (loss-making) — — n/m +28.07% (above 0%: growing) — 0.00% Compare
NKTX Nkarta, Inc. $112.5M — (loss-making) — — n/m −29.19% (below 0%: shrinking) 0.00% 0.00% Compare
CDXS Codexis, Inc. $111.7M — (loss-making) — (loss-making) −2.69% (below 0%: shrinking) n/m +48.60% (above 0%: growing) 76.45% (75.29%) Compare
ARMP Armata Pharmaceuticals, Inc. $111.5M — (loss-making) — (loss-making) +15.72% (above 0%: growing) n/m −17.98% (below 0%: shrinking) 100.00% (410.84%) Compare
HUMA Humacyte, Inc. $109.9M — (loss-making) — (loss-making) +34.88% (above 0%: growing) n/m +17.85% (above 0%: growing) (203.20%) (6,649.26%) Compare
NERV Minerva Neurosciences, Inc $109.8M — (loss-making) — (loss-making) — n/m −553.48% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $112.1M — — +25.30% — −1.55% 0.00% (27.39%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 20 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.74m 2.84m 18.00
2024 4.80m 2.36m 17.00
2023 5.90m 1.73m 42.00
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Coherus Oncology, Inc. (CHRS) Latest News

28 Oct

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

27 Oct

Impact 3 · · GlobeNewswire

14 Oct

Impact 3 · · GlobeNewswire

23 Sep

Impact 3 · · GlobeNewswire

12 Aug

Impact 4 · · The Motley Fool transcript

6 Aug

Impact 3 · · Moby transcript
Impact 3 · transcript

5 Aug

Impact 4 · · MarketBeat transcript
Impact 3 ·
Impact 3 ·

23 Jun

Impact 3 · · GlobeNewswire

14 May

Impact 3 · · Simply Wall St.

12 May

Impact 4 · · Moby
Impact 4 · · GuruFocus.com

11 May

Impact 4 · · MarketBeat
Impact 4 · · GlobeNewswire

1 Apr

Impact 4 · · Simply Wall St.

25 Mar

Impact 4 · · Zacks

14 Mar

Impact 4 · · MarketBeat

9 Mar

Impact 4 · · GuruFocus.com
Impact 4 · · MarketBeat
Impact 4 · · Associated Press Finance
Impact 4 · · GlobeNewswire
Impact 3 · · Zacks

8 Mar

Impact 4 · · MarketBeat

5 Mar

Impact 4 · · Simply Wall St.

18 Feb

Impact 4 ·

17 Feb

Impact 4 · · GlobeNewswire

12 Feb

Impact 3 · · GlobeNewswireSimply Wall St.MT NewswiresMT Newswires
stockrow.com/CHRS · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com